US Funding

Raising US investment as a UK or European founder? At some point the same question lands: do you need a Delaware C Corp, or can you raise into your UK Ltd? This guide compares both, covers the SEIS, EIS and QSBS tax picture, and explains what running the US entity involves.

US investors do not fund a pitch deck alone. They fund a company that holds up under due diligence. This checklist is a founder self-audit across the six areas investors examine before they wire: entity, cap table, IP, US employment, bookkeeping, and US presence. Find your gaps before they do.

Every UK or European founder eyeing US venture capital hits the same question early: do you need a US entity before American investors will talk? Flip too early and you create needless cost. Wait too long and you hit friction mid-raise. Here is the framework to get the timing right.

US venture capital is the deepest funding pool in the world, but American VCs judge European startups through a specific lens. Most founders pitch to the wrong one. Here is what US investors actually look for, where European companies fall short, and how to build foundations that make investor conversations land.

America turns 250 this year. For UK HealthTech founders, that milestone is worth more than a moment of reflection. The US digital health market raised $14.2 billion in 2025, AI-enabled health innovation is attracting record capital, and American buyers are ready to move. If you have been weighing the timing of a US expansion, the case for the next 12 to 24 months is unusually strong.

US election cycles create disproportionate board-level concern for European companies evaluating expansion. Political rhetoric intensifies and advisors recommend waiting for clarity. From a governance perspective, this instinct is understandable. From an operational and financial perspective, it's rarely justified. Economic fundamentals remain stable while delay introduces measurable strategic costs.